Package Leaflet: Information for the User
ReFacto AF 250 UI powder and solvent for solution for injection
ReFacto AF 500 UI powder and solvent for solution for injection
ReFacto AF 1000 UI powder and solvent for solution for injection
ReFacto AF 2000 UI powder and solvent for solution for injection
moroctocog alfa (recombinant human coagulation factor VIII)
Read all of this leaflet carefully before you start using this medicine because it contains important information for you.
Contents of the pack and other information:
ReFacto AF contains the active substance moroctocog alfa, human coagulation factor VIII. Factor VIII is necessary for blood to clot and stop bleeding. In patients with hemophilia A (congenital factor VIII deficiency), it is either not present or does not work properly.
ReFacto AF is used to treat and prevent (prophylaxis) bleeding episodes in adults and children of all ages (including newborns) with hemophilia A.
Do not use ReFacto AF
Talk to your doctor if you are unsure.
Warnings and precautions
Talk to your doctor or pharmacist before you start using ReFacto AF
Other medicines and ReFacto AF
Tell your doctor or pharmacist if you are using, have recently used, or might use any other medicines.
Pregnancy, breastfeeding, and fertility
If you are pregnant or breastfeeding, think you may be pregnant, or plan to become pregnant, talk to your doctor or pharmacist before using this medicine.
Driving and using machines
ReFacto AF has no influence on the ability to drive and use machines.
ReFacto AF contains sodium
After reconstitution, ReFacto AF contains 1.27 mmol (or 29 mg) of sodium (the main component of cooking/table salt) per vial. This is equivalent to 1.5% of the maximum recommended daily intake of sodium for an adult. Depending on your body weight and your dose of ReFacto AF, you may receive multiple vials. This should be taken into account if you are on a low-salt diet.
Follow the instructions for administration of this medicine exactly as told by your doctor. If you are unsure, talk to your doctor or pharmacist again.
Treatment with ReFacto AF should be started by a doctor who has experience in treating patients with hemophilia A. Your doctor will decide the dose of ReFacto AF you should receive. This dose and its duration will depend on your individual needs for factor VIII replacement therapy. ReFacto AF is given by injection into a vein and the injection takes several minutes. Injections of ReFacto AF can be given by patients or their caregivers, provided they have received appropriate training.
During your treatment, your doctor may change the dose of ReFacto AF you receive.
Talk to your doctor before traveling. When you travel, you should carry your factor VIII product in sufficient quantity for the planned treatment.
It is recommended that each time you use ReFacto AF, you record the name on the label and the batch number of the product. You can stick one of the detachable labels found on the vial to document the batch number in your diary or to report any side effects.
Reconstitution and administration
The instructions below are a guide for the reconstitution and administration of ReFacto AF. Patients should follow the specific reconstitution and administration instructions given by their doctors.
For reconstitution, use only the pre-filled syringe provided in the pack. For administration, other sterile disposable syringes can be used.
ReFacto AF is given by intravenous (IV) infusion after reconstituting the lyophilized powder for injection with the provided syringe of solvent, [a 9 mg/ml (0.9%) sodium chloride injection solution]. ReFacto AF should not be mixed with other infusion solutions.
Always wash your hands before performing reconstitution and administration. During the reconstitution procedure, aseptic technique (i.e., clean and germ-free) must be followed.
Reconstitution:
Note: If you use more than one vial of ReFacto AF per infusion, each vial must be reconstituted following the above instructions. The solvent syringe should be removed, leaving the vial adapter in place, and another large luer-lock syringe can be used to withdraw the reconstituted contents from each individual vial.
Note: If the reconstituted solution is not used immediately, the syringe cap should be carefully put back on. Do not touch the syringe tip or the inside of the cap.
ReFacto AF should be used immediately or within 3 hours after reconstitution. Before administration, the reconstituted solution can be stored at room temperature.
Administration (Intravenous Infusion):
ReFacto AF should be administered using the infusion set provided in this pack and the pre-filled syringe of solvent or a sterile disposable plastic syringe with a luer-lock connection.
Discard the unused solution, empty vial(s), and used needles and syringes in an appropriate container for disposing of medical waste, as these materials may harm others if not disposed of properly.
If you use more ReFacto AF than you should
Talk to your doctor or pharmacist.
If you stop using ReFacto AF
Do not stop using ReFacto AF without talking to your doctor.
If you have any other questions about the use of this medicine, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
Allergic reactions
If allergic reactions(anaphylactic) sudden, severeoccur, the infusion must be stopped immediately. You should talk to your doctor immediatelyif you experience any of the following early symptoms of allergic reactions:
Severe symptoms, such as difficulty breathing and fainting (or near-fainting), require rapid emergency treatment. Anaphylactic reactions sudden, severe are uncommon (may affect up to 1 in 100 patients)
Development of inhibitors
In children who have not received prior treatment with factor VIII medicines, inhibitor antibodies (see section 2) may occur very commonly (more than 1 in 10 patients); however, in patients who have received prior treatment with factor VIII (more than 150 days of treatment), the risk is uncommon (less than 1 in 100 patients). If this happens, the medicines you or your child are taking may stop working properly, and you or your child may experience persistent bleeding. In this case, contact your doctor immediately.
Very common side effects(may affect more than 1 in 10 patients)
Common side effects(may affect up to 1 in 10 patients)
Uncommon side effects(may affect up to 1 in 100 patients)
Reporting of side effects
If you experience any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly through the national reporting system listed in Appendix V. By reporting side effects, you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the outer carton and on the label of the vial after EXP. The expiry date refers to the last day of the month shown.
Store and transport refrigerated (2°C-8°C). Do not freeze to avoid damaging the pre-filled syringe containing the solvent.
For your convenience, the medicine can be removed from the refrigerator and stored at room temperature (up to 25°C) for a single period of up to 3 months. At the end of this room temperature storage period, the product should not be returned to the refrigerator, but should be used or discarded. Write the date you remove ReFacto AF from the refrigerator and store it at room temperature (up to 25°C) on the outer carton. Keep the vial in the outer carton to protect it from light.
The reconstituted product should be used within 3 hours after reconstitution.
The solution will be clear to slightly opalescent and colorless. Do not use this medicine if you notice it is turbid or contains visible particles.
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help protect the environment.
Composition of ReFacto AF
Appearance of the product and container contents
ReFacto AF is a glass vial with powder for injection and a solvent supplied in a pre-filled syringe.
The container contents are:
Marketing authorization holder
Pfizer Europe MA EEIG
Boulevard de la Plaine 17
1050 Brussels
Belgium
Manufacturer
Wyeth Farma S.A
Autovía del Norte A-1 Km 23
Desvío Algete Km 1
28700 San Sebastián de los Reyes
Madrid
Spain
You can request more information about this medicinal product by contacting the local representative of the marketing authorization holder.
België/Belgique/Belgien Luxembourg/Luxemburg Pfizer NV/SA Tel: +32 (0)2 554 62 11 | Lietuva Pfizer Luxembourg SARL filialas Lietuvoje Tel: +370 5 251 4000 |
Bulgaria Pfizer Bulgaria EOOD Tel: +359 2 970 4333 | Magyarország Pfizer Kft. Tel.: + 36 1 488 37 00 |
Ceská republika Pfizer, spol. s r.o. Tel: +420 283 004 111 | Malta Vivian Corporation Ltd. Tel: +356 21344610 |
Danmark Pfizer ApS Tlf.: +45 44 20 11 00 | Nederland Pfizer bv Tel: +31 (0)800 63 34 636 |
Deutschland PFIZER PHARMA GmbH Tel: +49 (0)30 550055-51000 | Norge Pfizer AS Tlf: +47 67 52 61 00 |
Eesti Pfizer Luxembourg SARL Eesti filiaal Tel: +372 666 7500 | Österreich Pfizer Corporation Austria Ges.m.b.H. Tel: +43 (0)1 521 15-0 |
Ελλάδα Pfizer Ελλάς Α.Ε Τηλ: +30 210 6785800 | Polska Pfizer Polska Sp. z o.o. Tel.: +48 22 335 61 00 |
España Pfizer S.L. Tel: +34 91 490 99 00 | Portugal Laboratórios Pfizer, Lda. Tel: +351 21 423 5500 |
France Pfizer Tél: +33 (0)1 58 07 34 40 | România Pfizer Romania S.R.L. Tel: +40 (0) 21 207 28 00 |
Hrvatska Pfizer Croatia d.o.o. Tel: + 385 1 3908 777 | Slovenija Pfizer Luxembourg SARL Pfizer, podružnica za svetovanje s podrocja farmacevtske dejavnosti, Ljubljana Tel: + 386 (0) 1 52 11 400 |
Ireland Pfizer Healthcare Ireland Unlimited Company Tel: 1800 633 363 (toll free) Tel: +44 (0)1304 616161 | Slovenská republika Pfizer Luxembourg SARL, organizacná zložka Tel: + 421 2 3355 5500 |
Ísland Icepharma hf. Sími: +354 540 8000 | Suomi/Finland Pfizer Oy Puh/Tel: +358 (0)9 430 040 |
Italia Pfizer S.r.l. Tel: +39 06 33 18 21 | Sverige Pfizer AB Tel: + 46 (0)8 550 520 00 |
Κύπρος Pfizer Ελλάς Α.Ε. (Cyprus Branch) Τηλ: +357 22817690 | |
Latvija Pfizer Luxembourg SARL filiale Latvija Tel: +371 670 35 775 |
Date of last revision of this leaflet:
Detailed information on this medicinal product is available on the European Medicines Agency website: https://www.ema.europa.eu.